Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Altimmune, Inc. (NASDAQ:ALT) is one of the best weight loss drugs on this list.

TheFly reported on May 18 that H.C. Wainwright reiterated its Buy rating on ALT while reducing its price objective from $25 to $20. The adjustment was attributed to dilution resulting from the company’s recent equity offerings, although the firm viewed the strengthened funding position and continued advancement of the MASH program as favorable developments.

Moreover, later on May 28, Altimmune, Inc. (NASDAQ:ALT) announced new 48-week results from its IMPACT Phase 2b trial evaluating pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH). The data showed that the investigational dual glucagon/GLP-1 receptor agonist significantly improved several cardiometabolic measures compared with placebo. Patients receiving the 1.8 mg dose experienced notable reductions in triglycerides and total cholesterol levels, along with continued weight loss, lower body mass index, reduced waist circumference, and improvements in both systolic and diastolic blood pressure.

Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?

michaelheim/Shutterstock.com

The findings were presented at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona. The Corporation also reported that pemvidutide maintained a favorable safety and tolerability profile through 48 weeks, with only a small percentage of patients discontinuing treatment due to adverse events. Previously disclosed trial data further demonstrated meaningful improvements in liver fibrosis and liver stiffness measures among patients treated with pemvidutide compared with those receiving placebo.

Altimmune, Inc. (NASDAQ:ALT) is a clinical-stage biopharmaceutical company developing pemvidutide, a dual GLP-1/glucagon receptor agonist for metabolic and liver diseases.

While we acknowledge the risk and potential of ALT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ALT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1